ScholarIQanswers from OpenAlex
Histone Deacetylase Inhibitors Research
TopicLeading institutions, researchers & key papers
Histone Deacetylase Inhibitors Research is a topic indexed in ScholarIQ from OpenAlex.
What is known about Histone Deacetylase Inhibitors Research?
ScholarIQrecord summary
This cluster of papers explores the role of histone deacetylases (HDACs) in regulating cellular functions, gene expression, and epigenetic modifications. It covers the use of HDAC inhibitors in cancer therapy, their impact on neurodegenerative disorders, and their involvement in protein complexes and enzymatic activity.
How many works does Histone Deacetylase Inhibitors Research have?
ScholarIQindexed works
Histone Deacetylase Inhibitors Research has 159 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Histone Deacetylase Inhibitors Research?
ScholarIQopenalex
The OpenAlex for Histone Deacetylase Inhibitors Research is on the source record.
What are the most-cited papers on Histone Deacetylase Inhibitors Research?
ScholarIQmost cited works
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard Petrillo, Delong Liu
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael T. Massengill, Mengyu Xie, Chris Massengill, David Noyes, Gary V. Martinez, Roha Afzal, Zhihua Chen, Xiubao Ren, Scott Antonia, Eric B. Haura, Brian Ruffell, Amer A. Beg
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.
Melinda C. Myzak, Philip Tong, Wan‐Mohaiza Dashwood, Roderick H. Dashwood, Emily Ho
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Yueyin Pan, Yuping Sun, Hong Wang, Tao Ouyang, Kangsheng Gu, Jifeng Feng, Xiaojia Wang, Shubin Wang, Tianshu Liu, Jinghua Gao, Massimo Cristofanilli, Zhiqiang Ning, Xianping Lu
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce, Lucely Cetina, José Luis Aguilar-Ponce, Óscar Arrieta, Aurora González‐Fierro, Alma Chávez‐Blanco, Erik de la Cruz-Hernandez, Maria Fernanda Vieira Cunha Camargo, Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas, Carlos Pérez‐Plasencia, Lucía Taja‐Chayeb, Talía Wegman-Ostrosky, Alma Luísa Revilla Vázquez, Alfonso Dueñas‐González
Where is Histone Deacetylase Inhibitors Research research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Histone Deacetylase Inhibitors Research is open access?
ScholarIQopen access share
87%OPEN ACCESS